Kallikrein related peptidase 2 targeting chimeric antigen receptor T-cell therapy - Fate Therapeutics

Alternative Names: Kallikrein-related peptidase 2 targeting iPSC-derived CAR T-cell therapy - Fate Therapeutics/Janssen Biotech

Latest Information Update: 09 Jan 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Fate Therapeutics
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

05 Jan 2023 Fate Therapeutics terminates its collaboration and option agreement with Janssen Biotech
05 Jan 2023 Discontinued - Preclinical for Prostate cancer in USA (Parenteral)
03 Nov 2022 Preclinical trials in Prostate cancer in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com